profit from every $100 of sales.
$0$100
Stoke Therapeutics
$26.68+1.83% today
+2.3% in 1 year
1-year low $22.501-year high $38.35
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Stoke Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $12.4 million in 2022 to $184 million in 2025, with -$6.89 million of profit last year.
SalesProfit
Stoke Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Stoke Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Stoke Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 12 | 9 | 37 | 184 | |
| – | – | – | – | |
| -104 | -115 | -101 | -21 | |
| -103 | -112 | -99 | -19 | |
| -101 | -105 | -89 | -7 | |
| -2.60 | -2.38 | -1.65 | -0.12 | |
| – | – | – | – | |
| -841.2% | -1,307.2% | -277.3% | -11.2% | |
| -814.7% | -1,192.5% | -243.4% | -3.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 256 | 228 | 272 | 418 |
| Cash | 114 | 191 | 128 | 84 |
| Total debt | 2 | 2 | 2 | 3 |
| Total liabilities | 71 | 69 | 43 | 66 |
| 185 | 160 | 229 | 352 | |
| 39 | 44 | 54 | 59 | |
| -44.0% | -56.1% | -34.6% | -4.6% | |
| -54.7% | -65.6% | -38.9% | -2.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -32 | -81 | -87 | 46 | |
| 4 | 2 | 0 | 1 | |
| -36 | -83 | -87 | 45 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 23 | 25 | 27 | 32 |
Valuation
- –
- –
- –
- 4.9×
- 9.5×
- 38.9×
- –
- 2.6%
- -0.4%
- 0.0%
Profitability
- 90.4%
- -11.2%
- -3.7%
- -555.6%
- -45.4%
- -39.7%
- -48.8%
- -38.3%
- -46.0%
- 449.1%
Growth
- +145.9%
- –
- +151.6%
- –
- +12.7%
Financial health
- -4.3×
- 0.01
- 0.8%
- -54.4×
- 8.99
- 8.99
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 8%of 952
Bottom 15%of 884
Top 3%of 886
Top 39%of 987
What analysts expect
- Average price target
- $43.86
- Range
- $35.00 – $60.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.79 | -0.80 | +1.3% |
| Mar 16, 2026 | -0.97 | -0.75 | −29.3% |
| Nov 4, 2025 | -0.65 | -0.54 | −20.4% |
| Aug 12, 2025 | -0.40 | -0.57 | +29.8% |
| May 13, 2025 | 1.90 | -0.37 | +613.5% |
| Mar 18, 2025 | -0.18 | -0.51 | +64.7% |
| Nov 5, 2024 | -0.47 | -0.52 | +9.6% |
| Aug 7, 2024 | -0.46 | -0.57 | +19.3% |
News
S&P 500, Dow Drop As Elevated Oil Prices Stoke Inflation Fears Ahead Of Fed Meeting Next Week — AAPL, AXP, CART, UBER In FocusYahoo Finance · Oct 23, 2026Baker Hughes sees no slowdown in energy projects despite higher rates as AI buildouts stoke LNG demandCNBC · Sep 14, 2026Prediction: Stoke Space Will IPO in 2027Yahoo Finance · Sep 11, 202610-year yield hits highest since January 2025 as higher oil prices stoke inflation worriesCNBC · Sep 1, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
42No pass
Philip Fisher
44No pass
Peter Lynch
54No pass
Joel Greenblatt
2No pass
Charlie Munger
36No pass
Terry Smith
36No pass
Questions about Stoke Therapeutics
Is Stoke Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Stoke Therapeutics AI analysis
What does Stoke Therapeutics do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. It is in Biotechnology.
Does Stoke Therapeutics pay a dividend?
No. Stoke Therapeutics does not pay a dividend at the moment.
Is Stoke Therapeutics stock halal?
Yes. Stoke Therapeutics passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Stoke Therapeutics stock done over the past year?
Up 2.3% over the past twelve months, to $26.68. It traded between $22.50 and $38.35 and is 30.4% below its high.
Who are Stoke Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Stoke Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.